{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:11:22Z","timestamp":1789506682194,"version":"build-2803163510"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015060","name":"Nagasaki University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.vaccine.2026.128964","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:21:37Z","timestamp":1784971297000},"page":"128964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged \u226560\u00a0years, Japan, October 2024\u2013April 2025"],"prefix":"10.1016","volume":"88","author":[{"given":"Haruka","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ataru","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Kutomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamehito","family":"Onoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruaki","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihide","family":"Ichigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kozai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Komazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konosuke","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128964_bb0005","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. Available from: https:\/\/www.who.int\/activities\/tracking-SARS-CoV-2-variants?utm_source=chatgpt.com."},{"key":"10.1016\/j.vaccine.2026.128964_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.126966","article-title":"Durability of COVID-19 vaccine and infection induced immunity: a systematic review and meta-regression analysis","volume":"54","author":"Moore","year":"2025","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128964_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10650","article-title":"Evaluation of waning of SARS-CoV-2 vaccine-induced immunity: a systematic review and meta-analysis","volume":"6","author":"Menegale","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128964_bb0020","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S1473-3099(24)00806-5","article-title":"The hospital and mortality burden of COVID-19 compared with influenza in Denmark: a national observational cohort study, 2022-24","volume":"25","author":"Bager","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"40","key":"10.1016\/j.vaccine.2026.128964_bb0025","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.15585\/mmwr.mm7240a3","article-title":"COVID-19-associated hospitalizations among U.S. adults aged \u226565 years - COVID-NET, 13 states, January-August 2023","volume":"72","author":"Taylor","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128964_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2026.128964_bb0035","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther"},{"key":"10.1016\/j.vaccine.2026.128964_bb0040","series-title":"On COVID-19 vaccines. Materials for the 58th meeting","article-title":"Health Sciences Council, Subcommittee on immunization and vaccines","author":"Ministry of Health, Labour and Welfare","year":"2024"},{"key":"10.1016\/j.vaccine.2026.128964_bb0045","author":"European Parliament"},{"key":"10.1016\/j.vaccine.2026.128964_bb0050","author":"Medicines and Healthcare products Regulatory Agency (MHRA)"},{"key":"10.1016\/j.vaccine.2026.128964_bb0055","author":"Japan Institute for Health Security"},{"key":"10.1016\/j.vaccine.2026.128964_bb0060","doi-asserted-by":"crossref","unstructured":"Laniece Delaunay C, Verdasca N, Monge S, Domegan L, Seve N, Buda S, et al. COVID-19 vaccine effectiveness against medically attended symptomatic SARS-CoV-2 infection among target groups in Europe, October 2024-January 2025, VEBIS Primary Care Network. Influenza Other Respi Viruses 2025;19(5):e70120.","DOI":"10.1111\/irv.70120"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128964_bb0065","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1038\/s41467-025-59344-7","article-title":"Early effectiveness of the BNT162b2 KP.2 vaccine against COVID-19 in the US Veterans Affairs Healthcare System","volume":"16","author":"Appaneal","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.vaccine.2026.128964_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128544","article-title":"Effectiveness of JN.1-adapted COVID-19 vaccine against medically attended SARS-CoV-2 infection and COVID-19 hospitalization in adults in Japan, from October 2024 to April 2025: versus","volume":"80","author":"Maeda","year":"2026","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128964_bb0075","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26007735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T20:37:46Z","timestamp":1789504666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26007735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":15,"alternative-id":["S0264410X26007735"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128964","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interim analysis of effectiveness of JN.1-adapted conventional and self-amplifying mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infection in adults aged \u226560\u00a0years, Japan, October 2024\u2013April 2025","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128964"}}